These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24881914)

  • 1. [Management of chronic myeloid leukemia for Japanese patients in the era of TKIs].
    Usui N
    Rinsho Ketsueki; 2014 May; 55(5):497-507. PubMed ID: 24881914
    [No Abstract]   [Full Text] [Related]  

  • 2. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
    Perrone S; Massaro F; Alimena G; Breccia M
    Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TKIs and transplant for chronic myeloid leukemia.
    Litzow MR
    Leuk Res; 2010 Feb; 34(2):137-8. PubMed ID: 19651441
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
    Smith CC; Shah NP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():121-7. PubMed ID: 22160023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
    Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Gong Z; Zheng L; Tang Z; Chen Z; Wang W; Bai S; Tang G; Medeiros LJ; Hu S
    Ann Hematol; 2017 Mar; 96(3):501-504. PubMed ID: 27915425
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
    Takahashi N
    Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
    Li MQ; Liu ZG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
    [No Abstract]   [Full Text] [Related]  

  • 12. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
    Imataki O
    Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing timing of secondary tyrosine kinase therapy in chronic myeloid leukemia.
    Radich JP
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S89-94. PubMed ID: 19254886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel therapeutic approach of Ph-positive leukemia: combination of tyrosine kinase inhibitors with other targeted drugs].
    Tauchi T
    Rinsho Ketsueki; 2013 Jun; 54(6):559-67. PubMed ID: 23823095
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
    Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
    Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic myeloid leukemia: reversing the chronic phase.
    Goldman JM
    J Clin Oncol; 2010 Jan; 28(3):363-5. PubMed ID: 20008612
    [No Abstract]   [Full Text] [Related]  

  • 17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia: Second-line drugs of choice.
    Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
    Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical management of patients with chronic myeloid leukemia.
    Cervantes F; Mauro M
    Cancer; 2011 Oct; 117(19):4343-54. PubMed ID: 21413002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.